Preview

Нефрология

Расширенный поиск

ОНКОМАРКЕРЫ ПРИ ОПУХОЛЯХ ПОЧЕЧНОЙ ПАРЕНХИМЫ

https://doi.org/10.24884/1561-6274-2006-10-1-77-85

Полный текст:

Об авторах

С. Х. Аль-Шукри
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, Санкт-Петербургский медико-технический институт
Россия
кафедра урологии  и  кафедра  патологической анатомии


М. Г. Рыбакова
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, Санкт-Петербургский медико-технический институт
Россия
кафедра урологии  и  кафедра  патологической анатомии


А. Э. Лукьянов
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, Санкт-Петербургский медико-технический институт
Россия
кафедра урологии  и  кафедра  патологической анатомии


Ю. А. Пономарева
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, Санкт-Петербургский медико-технический институт
Россия
кафедра урологии  и  кафедра  патологической анатомии


Список литературы

1. Bostwick DC, Murphy GP. Diagnosis and prognosis of renal cell carcinoma: highlights from an international consensus workgroup. Sem Urol Oncol 1998; 16: 46-52

2. АльШукри СХ, Ткачук ВН. Опухоли мочеполовых органов. СПб.: Питер, 2000; 60-78

3. Возианов АФ, Романенко АМ, Сайдакова НА и др. Экологический патоморфоз почечноклеточного рака в загрязненных радионуклидами регионах Украины. Журн АМН Украины 2002; (1): 120-131

4. Brkovic D, Riedash G, Staehler G. Urologe A1997; 36 (2): 103-108

5. Hafez KS,Novick AC, Campbell SC. Ibid1997; 157 (4): 2067-2070

6. Klein EA, Novick AC. Comprehensive textbook of genitourinary oncology. Baltimore, 1996; 207-217

7. Lerner SE, Hawkinks CA, Blute ML et al. Parthial nephrectomy. J Urol 1996; 155 (2): 61-66

8. Степанов ВН, Колпаков ИС, Серегин АВ. Материалы 3-й Всероссийской научн. конф. «Консервативная хирургия при опухоли почки» с участием стран СНГ. М., 1999; 151-158

9. Kovacs G, Akhtar M, Beckwith BH. The Heidelberg classification of renal cell tumors. J Pathol 1999; 183: 131-135

10. Kovacs G. Molecular genetics and diagnosis of renal cell tumors. Urologe A 1999; 38: 433-441

11. Delahunt B. Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol 1998; 15: 68-76

12. Fuhrman SA, Lasky LS, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol1982; 6: 655-663

13. Hemmerlein B, Markus A, Wehner M et al. Expression of acute and late-stage inflammatory antigens, c-fms, CSF-1, and human monocytic serine esterase 1, in tumor-associated macrophages of renal cell carcinomas. Cancer Immunol Immunother 2000; 49 (9): 485-492

14. Kowalczyk D, Skorupski W, Kwias Z, Nowak J. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Cancer Immunol Immunother 2001; 53 (5): 543-548

15. Shabtai M, Ye H, Frischer Z et al. Increased expression of activation markers in renal cell carcinoma infiltrating lymphocytes. J Urol 2002; 168 (5): 2216-2219

16. Zolota V, Tsamandas AC, Melachrinou M et al. Expression of CD44 protein in renal cell carcinomas: association with p53 expression. Urol Oncol 2002; 7(1): 13-17

17. Huang J, Soffer SZ, Kim ES et al. p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease.J Pediatr Surg 2002; 37 (3): 523-527

18. Yoshioka K, Nakamura S.Chromosome 9 and 17 aberrations and p53 gene deletion detected by fluorescence in situ hybridization in renal-cell carcinoma. Mol Urol 2001; 5 (1): 11-17

19. Hashimoto H, Sue Y, Saga Y et al. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter. Int J Urol 2000; 7 (12): 457-463

20. Rioux-Leclercq N, Turlin B, Bansard J et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000; 55 (4): 501-505

21. Haitel A, Wiener HG, Blaschitz U et al. Biologic behavior and p53 overexpression in multifocal renal cell carcinoma of clear cell type: an immunohistochemical study correlating grading, staging, and proliferation markers. Cancer 1999; 85 (4): 432-438

22. Chemeris G, Loktinov A, Rempel A et al. Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors. Virchows Arch 1995; 426 (6): 563-569

23. Ghanem MA, Van der Kwast TH, Den Hollander JC et al. The prognostic significance of apoptosisassociated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma. J Cancer 2001;85 (10): 1557-1563

24. Paraf F, Gogusev J, Chretien Y, Droz D. Expression of bcl-2 oncoprotein in renal cell tumours. J Pathol 1995; 177 (3): 247-252

25. Chandler D, elNaggar AK, Brisbay S et al. Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum Pathol1994; 25 (8): 789-796

26. Velickovic M, Delahunt B, McIver B, Grebe SK. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol 200; 15 (5): 479-485

27. Brenner W, Farber G, Herget T et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002 May; 99 (1): 53-57

28. Haitel A, Wiener HG, Neudert B et al. Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology 2001; 58 (3): 477-481

29. Yokogi H. Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content in patients with renal cell carcinoma. Cancer1996;78 (4): 819-826

30. Leroy X, Zerimech F, Zini L et al. MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. Am J Clin Pathol 2002; 118 (1): 47-51

31. Kraus S, Abel PD, Nachtmann C et al. MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis. Hum Pathol 2002; 33 (1): 60-67

32. Fujita K, Denda K, Yamamoto M et al. Expression of MUC1 mucins inversely correlated with postsurgical survival of renal cell carcinoma patients. Br J Cancer1999;80 (1-2): 301-308

33. Rotter M, Block T, Busch R et al. Expression of HER-2/neu in renal-cell carcinoma. Correlation with histologic subtypes and differentiation. J Cancer 1992; 52 (2): 213-217

34. Fontana LO, Garcia Garcia F, Arcas Martinez Salas I et al. The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival. Arch Esp Urol2002; 55(7): 792-796

35. Ramp U, Bretschneider U, Ebert T et al. Prognostic implications of CD95 receptor expression in clear cell renal carcinomas. Hum Pathol 2003; 34 (2): 174-179

36. Rasmuson T, Grankvist K, Jacobsen J, Ljungberg B. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma. Eur J Cancer 2001; 37 (17): 2199-2203

37. Dosquet C, Coudert MC, Lepage E et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res 1997; 3 (12 Pt 1): 2451-2458

38. Inoue K, Kamada M, Slaton JW et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 2002; 8 (6): 1863-1870

39. Alami J, Williams BR, Yeger H. Expression and localization of HGF and met in Wilms’ tumours. J Pathol 2002; 196 (1): 76-84

40. Stumm G, Eberwein S, Rostock-Wolf S et al. Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer1996; 69 (1): 17-22

41. Ghanem MA, van Steenbrugge GJ, Sudaryo MK et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 2003; 56 (2): 107-113

42. Edgren M, Lennernas B, Larsson A, Kalkner K. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma. Anticancer Res 2001; 21(2B): 1423-1429

43. Schraml P, Struckmann K, Hatz F et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002; 196 (2): 186-193

44. Ottaiano A, Pisano C, De Chiara A et al. CD40 activation as potential tool in malignant neoplasms. Tumor2002; 88 (5): 361-366

45. Ghanem M.A.,Van Der Kwast TN,Sudaryo MK. Expression and prognostic value of CD44 isoforms in nephroblastoma (Wilms tumor).J Urol 2002; 168 (2): 681-686

46. Miyake H, Eto H, Arakawa S et al. Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer. J Urol 2002; 167 (3): 1282-1287

47. RiouxLeclercq N, Epstein JI, Bansard JY et al. Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol 2001; 32 (11): 1209-1215

48. Li N, Tsuji M, Kanda K et al. Analysis of CD44 isoform v10 expression and its prognostic value in renal cell carcinoma. BJU Int2000; 85 (4): 514-518

49. Fischer C, Georg C, Kraus S et al. CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma. Anticancer Res1999; 19 (2C): 1513-1517

50. de Alava E, Panizo A, Sola I et al. CD44v6 expression is related to progression in renal epithelial tumours. Histopathology 1998; 33 (1): 39-45

51. Gunthert U, Stauder R, Mayer B et al. Are CD44 variant isoforms involved in human tumour progression? Cancer Surv 1995; 24: 19-42

52. Gilcrease MZ, Guzman-Paz M, Niehans G et al.Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer 1999; 86 (11): 2320-2326

53. Francois C, van Velthoven R, De Lathouwer et al. Galectin-1 and galectin-3 binding pattern expression in renal cell carcinomas. Am J Clin Pathol1999; 112 (2): 194-203

54. Ghanem MA, Van Der Kwast TH, Den Hollander JC et al. Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer 2001; 92 (12): 3120-3129

55. Ramp U, Jaquet K, Reinecke P et al. Acquisition of TGF-beta 1 resistance: an important progression factor in human renal cell carcinoma. Lab Invest 1997; 76 (5): 739-749

56. Papadopoulos I, WeichertJacobsen K, Wacker HH, Sprenger E. Correlation between DNA ploidy, proliferation marker Ki-67 and early tumor progression in renal cell carcinoma. A prospective study.Eur Urol1997; 31(1): 49-53

57. Haitel A, Wiener HG, Migschitz B et al. Proliferating cell nuclear antigen and MIB-1. An alternative to classic prognostic indicators in renal cell carcinomas. Am J Clin Pathol 1997; 107 (2): 229-235

58. Mitsumori K, Kittleson JM, Itoh N et al. Chromosome 14q LOH in localized clear cell renal cell carcinoma. J Pathol 2002; 198 (1): 110-114

59. Diakoumis E, Sourvinos G, Kiaris H et al. Genetic instability in renal cell carcinoma. Eur Urol1998; 33 (2): 227-232

60. Willers CP, Siebert R, Bardenheuer W et al. Genetic instability of 3p12-p21-specific microsatellite sequences in renal cell carcinoma. Br J Urol 1996; 77 (4): 524-529

61. Terpe HJ, Storkel S, Zimmer U et al. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Br J Urol 1997; 87 (4): 424-429

62. Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 1995; 55 (2): 224-227

63. Polascik TJ, Cairns P, Epstein JI et al. Distal nephron renal tumors: microsatellite allelotype. Cancer Res1996; 56 (8): 1892-1895

64. Fujioka T, Hasegawa M, Suzuki Y et al. Telomerase activity in human renal cell carcinoma. Int J Urol2000; 7 (1): 16-21

65. Dahse R, Fiedler W, Junker K et al. Telomerase activity and telomere lengths: alterations in renal cell carcinomas. Kidney Int1999; 56 (4): 1289-1290

66. Tuzel E, Kirkali Z, Yorukoglu K et al. Metallothionein expression in renal cell carcinoma: subcellular localization and prognostic significance. J Urol 2001; 165 (5): 1710-1713

67. Wang L, Darling J, Zhang JS et al. Incidence of apoptosis and metallothionein expression in renal cell carcinoma. Oncogene1998; 16 (5): 635-642

68. Braun C, Engel M, Seifert M et al. Expression of calpain I messenger RNA in human renal cell carcinoma: correlation with lymph node metastasis and histological type. Int J Cancer 1999; 84 (1): 6-9

69. Takenawa J, Kaneko Y, Kishishita M et al. Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy. Jpn J Cancer Res1994;89(3): 324-329

70. Takashi M, Sakata T, Kato K. Use of serum gamma-enolase and aldolase A in combination as markers for renal cell carcinoma.Jpn J Cancer Res1993; 84 (3): 304-309

71. Kitamura Y, Watanabe M, Komatsubara S, Sakata Y. Urinary excretion of glycine.prolile dipeptidile aminopeptidase, N-acetyl-beta-D-glucosaminidase, alanine aminopeptidase and low molecular protein in patients with renal cell carcinoma. Hinyokika Kiyo1990; 36 (5): 535-539

72. Nakagawa Y, Sirivongs D, Novy MB et al. Nephrocalcin: biosynthesis by human renal carcinoma cells in vitro and in vivo. Cancer Res 1999; 52 (6): 1573-1579

73. Balitskaia OV, Berdinskikh NK, Kononenko NG. The possibilities of using the free polyamines of the peripheral blood as biochemical tumor markers in nephroblastoma in children. Vopr Onkol1992; 38 (6): 674-682


Для цитирования:


Аль-Шукри С.Х., Рыбакова М.Г., Лукьянов А.Э., Пономарева Ю.А. ОНКОМАРКЕРЫ ПРИ ОПУХОЛЯХ ПОЧЕЧНОЙ ПАРЕНХИМЫ. Нефрология. 2006;10(1):77-85. https://doi.org/10.24884/1561-6274-2006-10-1-77-85

For citation:


Al-Shukri S.K., Rybakova M.G., Lukyanov A.E., Ponomareva Yu.A. ONCOMARKERS IN TUMORS OF RENAL PARENCHYMA. Nephrology (Saint-Petersburg). 2006;10(1):77-85. (In Russ.) https://doi.org/10.24884/1561-6274-2006-10-1-77-85

Просмотров: 48


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)